XRCC2 and central nervous system cancer: Based on the role of XRCC2 in glioma progression, it was necessary to screen for anti-glioma drugs that target XRCC2. Therefore, we used the CMap to explore anti-glioma micromolecular drugs that can target XRCC2. The results of CMap analysis suggested that doxazosin, quinostatin, canavanine, and chrysin have a high potential for clinical application against glioma by targeting XRCC2 Table 4.